Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 22

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 22
---
 have or share voting or investment control, in addition to anyone who receives material non-publicinformation (“MNPI”) from an Adaptive insider or is otherwise designated under the policy (collectively, “covered persons”). The insider trading policy also applies to Adaptive itself when it transacts in securities, including to generally prohibit the grant of equity awards while in possession of MNPI and to provide guidelines around repurchases of our securities, which would generally be made only pursuant to a Rule 10b5-1 trading plan established when we are not in possession of MNPI. Our insider trading policy is designed to promote compliance with applicable insider trading laws, rules and regulations and applicable listing standards. Among other things, our insider trading policy (i) prohibits trading 15

by covered persons in our securities while in possession of MNPI about Adaptive, except under trading plans that meet the requirements of Rule 10b5-1under the Exchange Act, or in the securities of any other company with respect to which such covered persons have received MNPI as a result of their relationship with or employment by Adaptive, (ii) prohibits disclosing MNPI to others who may trade in Adaptive securities or in the securities of any other publicly traded company on the basis of such MNPI, and (iii) specifies our blackout periods (and who is subject to such periods), our insider trading windows and pre-clearanceprocedures (and who is subject to such procedures) and requirements and procedures regarding Rule 10b5-1trading plans. A copy of our insider trading policy was filed as Exhibit 19 to our 2024 Annual Report on Form 10-Kfiled with the SEC on March 3, 2025. CODE OF CONDUCT We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. The code is updated periodically; a current copy is posted on our website at www.adaptivebiotech.com. While we make ministerial and technical amendments to the code of conduct and ethics from time to time, if we make any substantive amendments to, or grant any waivers from, the code for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K. 16

DIRECTOR COMPENSATION The following table presents the total compensation for each person who served as a non-employeemember of our board of directors at any time